[Correspondence] Distinct representation of muscle weakness in QMG and MG-ADL – Authors' reply

We would like to thank Robert de Meel and colleagues for their interest in and comments on our Article.1 The sub-analysis correlations between MG-ADL and QMG data in the phase 2 eculizumab trial2 were based on change from baseline to week 16 in 13 patients who were refractory to immunosuppressive treatments. No correlation analyses have been done on the phase 3 worst-rank data.

Source: Lancet Neurology - February 14, 2018 Category: Neurology Authors: James F Howard, Fanny O'Brien, Jing-Jing Wang Tags: Correspondence Source Type: research